PREPAREDNESS TODAY, SAFER TOMORROW.

The New Way Forward

Who we protect will not change, but how we protect them will. Emergent is leading the new way forward for public health.

Learn more

Capabilities

We are a leading public health company that delivers protective and life-saving solutions to communities around the world.

  • Commercial Products

    We offer commercialized products that address endemic public health threats such as the opioid epidemic.

  • Medical Countermeasures

    We specialize in developing, manufacturing, and supplying medical countermeasures for national security and public health preparedness.

  • Strategic Partnerships

    We leverage our specialized in-house capabilities to support biopharma innovators, governments and non-government organizations with their development and manufacturing needs. ​

At Emergent, our mission is to protect and save lives.

View our 2024 Annual Report

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of over-the-counter (OTC) NARCAN® Nasal Spray.
Read More

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025.
Read More

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation

GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions, Inc. (NYSE: EBS) announced it made a voluntary prepayment of $100 million under its outstanding term loan facility in late December 2025 using cash on hand.
Read More
READ ALL NEWS